×
Alector EBIT Margin 2017-2025 | ALEC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Alector ebit margin from 2017 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
View More
Alector EBIT Margin 2017-2025 | ALEC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Alector ebit margin from 2017 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$246.7B
Amgen (AMGN)
$159.1B
Gilead Sciences (GILD)
$146.4B
Vertex Pharmaceuticals (VRTX)
$100.2B
Bristol Myers Squibb (BMY)
$98.4B
GSK (GSK)
$80.7B
CSL (CSLLY)
$70.8B
Regeneron Pharmaceuticals (REGN)
$60.6B
Alnylam Pharmaceuticals (ALNY)
$60.1B
Argenex SE (ARGX)
$40.2B
Insmed (INSM)
$26.9B
BioNTech SE (BNTX)
$26.8B
Royalty Pharma (RPRX)
$21B
Biogen (BIIB)
$20.4B
Incyte (INCY)
$16.7B
Illumina (ILMN)
$15.6B
Genmab (GNMSF)
$15.3B
Genmab (GMAB)
$15.3B
Ascendis Pharma (ASND)
$11.9B
BioMarin Pharmaceutical (BMRN)
$11B
QIAGEN (QGEN)
$10.9B
Moderna (MRNA)
$10.9B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Exelixis (EXEL)
$10.1B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.6B
Bio-Techne Corp (TECH)
$8.6B
Blueprint Medicines (BPMC)
$8.3B
Halozyme Therapeutics (HALO)
$8.2B
Roivant Sciences (ROIV)
$8B